Bodenstedt Matthias 4

What Happened
Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (MLTX), disposed of 13,653 shares on May 11, 2026. The weighted-average sale price was $20.02 per share, generating total proceeds of approximately $273,333. This was a sale (not a purchase) and thus typically reflects liquidity or routine trading rather than a direct bullish signal.

Key Details

• Transaction date: May 11, 2026; reported on Form 4 filed May 13, 2026 (timely within the 2‑business‑day window).
• Transaction type/code: Open‑market sale (S).
• Shares sold: 13,653; weighted-average price: $20.02; total proceeds ≈ $273,333.
• Price range: Shares were sold in multiple transactions at prices ranging from $19.50 to $20.83 (weighted average reported). Per the filing, a full breakdown by price is available upon SEC or issuer request.
• Shares owned after the transaction: Not disclosed in the provided filing.
• Footnotes: The sales were executed pursuant to a Rule 10b5‑1 trading plan adopted December 10, 2025.

Context
Sales executed under a pre-established Rule 10b5‑1 plan are scheduled trading arrangements that allow insiders to sell shares at predetermined times and are commonly used to avoid appearance of trading on inside information. The filing appears timely and does not, by itself, indicate the insider’s view of the company’s prospects.